SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is trending as investors weigh conflicting signals between reports of potential product delays and the company's firm rebuttal that its AI infrastructure roadmap remains intact. Market sentiment is heavily divided, with some community members frustrated by the stock's recent volatility and alleged price manipulation, while others maintain conviction in the long-term fundamentals of the AI compute cycle.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is generating significant community attention following an upbeat revenue forecast and an upward revision to its annual delivery guidance, which has fueled a debate over whether these positive operational updates justify recent share dilution or if the stock remains a high-volatility trading vehicle. Investors are heavily focused on the company's scaling potential and the upcoming R2 launch, while discussions remain polarized between long-term bulls betting on a fundamental turnaround and skeptical traders concerned about the repeated pattern of capital raises capping rally momentum.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

COMPASS Pathways is currently trending due to positive Phase 3 trial data for its COMP360 therapy, which demonstrates durable therapeutic benefits and a strong safety profile. Investors are actively discussing the company's regulatory momentum following FDA support for a rolling NDA submission, while clinical milestone catalysts and potential for breakthrough treatment in depression continue to drive community enthusiasm.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is currently seeing heightened investor interest driven by a significant price target hike from Goldman Sachs and strategic partnerships, including new collaborations in autonomous driving. While the broader semiconductor sector remains volatile due to concerns over AI-cycle sustainability, the community remains actively divided between bullish sentiment regarding the company's data center and AI compute roadmap and bearish concerns about stretched valuations.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Cloud Memory Business Unit (CMBU), Core Data Center Business Unit (CDBU), Mobile and Client Business Unit (MCBU), and Automotive and Embedded Business Unit (AEBU). The CMBU segment focuses on memory solutions for large hyperscale cloud customers and High-Bandwidth Memory for all data center customers. The CDBU segment is involved in memory solutions for mid-tier cloud, enterprise, and OEM data center customers and storage solutions for all data center customers. The MCBU segment focuses on memory and storage solutions for the mobile and client segments. The AEBU segment is involved in memory and storage solutions for the automotive, industrial, and consumer segments. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is trending as a broader semiconductor sell-off, sparked by Samsung's earnings and concerns over AI cycle sustainability, triggers heavy volatility. Investors are actively debating whether this pullback is a temporary reset for long-term growth or the beginning of a larger correction, with many retail participants discussing whether to capitalize on the dip or brace for further downside.

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The firm's product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. It is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.

Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals is trending following a massive $10 billion acquisition by Vertex Pharmaceuticals, a deal that represents a significant premium for shareholders. Investors are now actively debating whether to lock in gains or monitor the stock for potential merger arbitrage opportunities as the sector continues to see intense M&A activity.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is facing intense volatility as traders debate whether the current semiconductor pullback is a temporary buying opportunity for the AI cycle or the beginning of a deeper trend reversal. The community is sharply divided, with many actively trading the aggressive swings while others warn of technical breakdown and further downside risk.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending as investors anticipate a major pivotal Phase 3 trial initiation for its NSCLC pipeline, further validating the commercial potential of its Aglatimagene platform. Community discussion is focused on the company's valuation gap, the upcoming BLA submission for its prostate cancer asset, and speculation regarding its long-term potential as a premier acquisition target for major pharmaceutical companies.

VanEck ETF Trust - VanEck Semiconductor ETF

VanEck Semiconductor ETF

Semiconductor stocks are trending as investors weigh intense AI infrastructure demand against growing concerns over sector overvaluation, crowded positioning, and potential volatility from high-profile earnings reports. Community discussions are heavily focused on navigating this rotation, with many traders debating whether the rally is a structural boom or a speculative bubble prone to a sharp pullback.

Palladyne AI Corp. engages in the design, development, and manufacture of industrial robotic systems that augment human performance by combining human intelligence, instinct, and judgment with the strength, endurance, and precision of machines to enhance employee safety and productivity. Its products include Palldyne IQ and Palladyne Pilot. The company was founded by Fraser M. Smith and Benjamin G. Wolff in 2015 and is headquartered in Salt Lake City, UT.

Palladyne AI Corp.

Palladyne AI is currently trending as investors focus on its recent U.S. Army contracts for SwarmOS and Gremlin-X technology, which validate the company's autonomous capabilities in real-world combat environments. The community is actively debating the company's long-term potential as a defense software prime, with many traders closely monitoring high short interest and technical accumulation levels amidst broader sector rotation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ONCY Stock Surged Today – Here’s What Securing A Key Immunotherapy Patent Means For Oncolytics

Equity

The U.S. Patent and Trademark Office granted a new patent covering key aspects of its proprietary manufacturing process for its investigational cancer immunotherapy Pelareorep.

ONCY Stock Heads For Sixth Straight Session Of Gains – Lead Therapy Shines in Early Combination Treatment Study

Oncolytics Biotech said preclinical data showed its experimental immunotherapy produced stronger anti-tumor effects in combination therapy, supporting future studies in pancreatic and colorectal cancers.

Penny Stock Oncolytics Biotech Says Colorecatal Cancer Drug's Durability Tops Historical Benchmarks

Oncolytics shares rise as pelareorep shows 19.5-month response durability and higher response rates in colorectal cancer study.read more...

Oncolytics Biotech Inc. (NASDAQ:ONCY) Given Average Rating of "Moderate Buy" by Analysts

Shares of Oncolytics Biotech Inc. (NASDAQ:ONCY - Get Free Report) have received an average rating of "Moderate Buy" from the five brokerages that are currently covering the firm, MarketBeat reports...

Q1 EPS Forecast for Oncolytics Biotech Lifted by Analyst

Oncolytics Biotech Inc. (NASDAQ:ONCY - Free Report) - Equities research analysts at HC Wainwright upped their Q1 2026 EPS estimates for Oncolytics Biotech in a research note issued on Friday, April 10th. HC Wainwright analyst P. Trucchio now anticipates that the company will earn ($0.03) per share f...

Equities Analysts Issue Forecasts for ONCY Q1 Earnings

Oncolytics Biotech Inc. (NASDAQ:ONCY - Free Report) - Stock analysts at HC Wainwright issued their Q1 2027 EPS estimates for Oncolytics Biotech in a report released on Friday, April 10th. HC...

Q1 Earnings Estimate for ONCY Issued By Zacks Research

Oncolytics Biotech Inc. (NASDAQ:ONCY - Free Report) - Zacks Research issued their Q1 2026 earnings estimates for shares of Oncolytics Biotech in a note issued to investors on Tuesday, April 7th...

What is Zacks Research's Forecast for ONCY FY2026 Earnings?

Oncolytics Biotech Inc. (NASDAQ:ONCY - Free Report) - Equities research analysts at Zacks Research issued their FY2026 earnings per share estimates for Oncolytics Biotech in a research note issued to...

Oncolytics Biotech Inc. (NASDAQ:ONCY) Receives Consensus Rating of "Moderate Buy" from Analysts

Oncolytics Biotech Inc. (NASDAQ:ONCY - Get Free Report) has been given an average rating of "Moderate Buy" by the five research firms that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, two...

Oncolytics Biotech (NASDAQ:ONCY) Upgraded to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Oncolytics Biotech from a "strong sell" rating to a "hold" rating in a research report on Saturday...

Oncolytics Biotech, Inc. engages in the provision of development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolation of the reovirus that induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses. The company was founded by Matthew C. Coffey and Bradley George Thompson on April 2, 1998 and is headquartered in Calgary, Canada.

Oncolytics Biotech, Inc.

Extremely Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

ONCYOncolytics Biotech, Inc.

Fundamentals

Latest ONCY News